Trial Profile
A phase 3 study of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Malignant carcinoid syndrome
- Focus Pharmacokinetics; Registrational
- Sponsors Biodexa Pharmaceuticals
- 16 May 2023 According to Biodexa Pharmaceuticals, 20-F filing, Midatech has changed its name to Biodexa Pharmaceuticals
- 29 Jan 2019 According to a Midatech media release, this trial is expected to begin in H2 2019.
- 06 Sep 2018 New trial record